Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma - Wikidata - wikimedia - TriplyDB

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

http://www.wikidata.org/entity/Q33417472

about

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas Phase I study of pazopanib plus TH-302 in advanced solid tumors.Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology.Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.[Soft tissue sarcoma: a report of 33 cases]Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.Phase III Soft Tissue Sarcoma Trials: Success or Failure?Current and advancing systemic treatment options for soft tissue sarcomas.Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.Virus-directed enzyme prodrug therapy and the assessment of the cytotoxic impact of some benzimidazole derivatives.Emerging targets for radioprotection and radiosensitization in radiotherapy.CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.

P2860

Q26774750-BAE6B333-A6B9-4AD8-8DA5-8C9CA43B3F77 Q27025007-C554D9AD-AA95-4C92-89BB-ADB0528C924F Q28078116-F4A7F4DB-B1BD-4099-9768-98E577067C25 Q33439635-91471F36-5F3D-4D23-81D1-FFDF799B121D Q33657282-2852DA4C-99C9-4D99-94F0-89C50ACAAFB0 Q35637224-A78C5483-FC6D-4075-A435-0B7A129E440D Q35987173-764CF4E8-801C-40CC-B177-1DB76AC41380 Q35993104-2E4E4355-FFE5-4AA9-96C6-4DD674DA151A Q36106434-8A28834A-3F5D-4E85-9C4D-26A01DA13F1F Q36286658-D71E81AD-D3EF-4022-B370-5ECB205D7D41 Q36680253-65279D30-D6DB-48AB-AA34-C7E767E3FBCF Q36706902-2AE6DD91-A015-4D60-8F53-3C5C1C4382A6 Q36759062-B974B85C-6E41-465E-AA8F-F3EA43348951 Q37137443-CFD8BCB6-4758-4648-BB0C-CAFF067E955D Q37283967-937220AF-E4D1-4EE2-ADD0-597BC13FE51C Q37716872-498A93D8-B4C8-4F70-B6D6-23552D24AD50 Q38563242-11C3A68D-DCB1-4DA2-B3C1-1B876751EF49 Q38591828-75FBA9F8-28B8-471C-B392-BB37B87EA0C0 Q38696221-2C544794-6A07-46EA-B4E9-507EB8429374 Q38869603-6B147512-E7EE-449A-80F0-4BA416FB9A44 Q38885166-C7FC26F4-10AD-4775-A88F-6AD02AE021E8 Q39668588-ADC35A03-26EA-4BC0-9120-589B1268DB21 Q39984948-2760E253-A8CC-4958-B746-E50DD5E3D56F Q39985326-1B78CAAF-A500-4B10-9CC5-FB1E70B858EA Q40862337-D2683563-60E4-4C79-B2EE-DAF5CDEFECE6 Q41007674-A674C932-8C49-472A-8597-1B1CAC76FCE9 Q41467964-D6C2438B-F9D9-4D10-811E-2A0D71A25286 Q41712371-92C80111-7E44-4D92-993D-BFFBD0B641F6 Q42417074-1B7E078F-D7B1-4B6F-9143-BD444B49C6B5 Q42488078-9747279B-A928-4CB0-AFCA-B78D57153DDE Q42835560-378093DD-9A36-4682-9CC0-51F71D47C66B Q46013875-0570EFE9-AE08-48AC-8F56-E01CDB05ABB3 Q46018609-55E03B8A-B194-41E1-A977-7C291638E4B1 Q48114384-A732011E-D650-4749-925E-A38178940D19 Q48371418-E506E3E9-4831-4060-97D7-4921BFB026BE Q55555244-323B058E-1642-492B-997E-28DDE060B69B

P2860

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

http://www.wikidata.org/entity/Q33417472

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@ast

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@en

type

label

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@ast

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@en

prefLabel

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@ast

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@en

P1433

Q33417472-15B3B994-E7C2-4B0A-8E2A-CD6B8EE785B3

P1476

Q33417472-F25458DF-5E48-4CF0-B4C4-1883B9F64C38

P2093

Q33417472-06BE802D-2752-47B3-81E6-A66C854920B3

Q33417472-1BA1EBCB-A0E8-4CAD-A6B0-7EE20EB7282C

Q33417472-2C28B61E-E6AB-4222-A219-19E0F5D1BB96

Q33417472-611AEE9E-28C6-4F16-974C-738EA2E1F9A0

Q33417472-7DA0F3C7-EBEB-436C-ACB5-7A8E57A75475

Q33417472-C045B000-5FFA-43BF-B167-BBB1E84AFA09

Q33417472-CBAD342B-99C4-42FF-93FB-4EE6B022B092

Q33417472-E40F236C-5796-4C7B-8B0F-4BD71FC019B0

Q33417472-E4A294F4-D452-46A1-88DE-CA4AD4068F74

P2860

Q33417472-07CCFB61-CBE3-4C48-BA08-DC26905140F2

Q33417472-1977C77C-D945-4A5D-829D-105D0262DF86

Q33417472-1AFD7D83-C6BD-41D4-90A6-795C49C65352

Q33417472-22AE86AF-6013-416D-B5C6-3FC9DE57C998

Q33417472-2CD670E5-CEEA-414E-A6DC-C67D86F419F5

Q33417472-2E92303A-7219-4429-BB65-4E0ADC86F00D

Q33417472-2F970743-C35F-4C08-950B-E9CABF47D798

Q33417472-3426AF1A-C7CD-444B-9DAC-20C9143DFB4F

Q33417472-3A4E5C96-1E8D-4EC4-B757-209F6315C49F

Q33417472-3F70EC86-2B86-44F1-B782-D680A718E555

P304

Q33417472-3981F83E-B8EF-4BB0-BAA9-FE91A71C92F5

P31

Q33417472-97F7F942-410F-4786-A16A-166BC9570345

P356

Q33417472-F0461BCF-C8AA-4B6B-AA23-1A688B654F0F

P407

Q33417472-92F5C2D5-546E-475B-AC12-83A5FA632012

P433

Q33417472-95662BBA-215B-4514-9AFB-FCDB2734CDCD

P478

Q33417472-E28E2FBC-DB31-4A0B-8ADA-878F86E473A5

P50

Q33417472-5E56A386-7FF9-442D-9A91-E1CEF29604D8

P577

Q33417472-DC3D1B41-82AC-4F05-BEC3-F11D8433B4B5

P698

Q33417472-8427C30B-B750-4626-9487-885781FE57DD

P921

Q33417472-85AA010A-1170-4157-AE91-34CAB9502CFD

P932

Q33417472-CEBA5BD8-0DA8-43BA-8087-78B8AC9AF6D5

P356

JCO.2013.54.3660

P1433

Journal of Clinical Oncology

P1476

Phase II study of the safety a ...... h advanced soft tissue sarcoma

@en

P2093

Andrew E Hendifar

http://www.w3.org/2001/XMLSchema#string

Brian A Van Tine

http://www.w3.org/2001/XMLSchema#string

Douglas R Adkins

http://www.w3.org/2001/XMLSchema#string

James E Butrynski

http://www.w3.org/2001/XMLSchema#string

Kristen N Ganjoo

http://www.w3.org/2001/XMLSchema#string

Lee D Cranmer

http://www.w3.org/2001/XMLSchema#string

Sant P Chawla

http://www.w3.org/2001/XMLSchema#string

Scott H Okuno

http://www.w3.org/2001/XMLSchema#string

Stew Kroll

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Exploiting tumour hypoxia in cancer treatment

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Targeting hypoxic tumour cells to overcome metastasis.

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

Histology-driven chemotherapy of soft-tissue sarcoma.

P304

3299-3306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.54.3660

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25185097

http://www.w3.org/2001/XMLSchema#string

P921

P932

4588714

http://www.w3.org/2001/XMLSchema#string